MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

Read original · https://www.prnewswire.com/news-releases/minimed-to-expand-sensor-portfolio-with-integrated-dual-glucose-ketone-sensors-made-by-abbott-302789583.html

Search tags

What matters in this story

MiniMed and Abbott have entered an expanded agreement to commercialize dual glucose-ketone sensors integrated with MiniMed smart dosing systems. — Integration of real-time ketone monitoring to prevent DKA is a significant technological leap in diabetes care that could drive adoption and market share for both companies.

+0.60

The dual sensors are designed to enable early detection of rising ketones to prevent diabetic ketoacidosis (DKA), reducing the need for manual finger-stick or urine tests. — Solving a high-severity medical complication (DKA) increases the clinical value proposition and potential pricing power of the combined system.

+0.40

Abbott's dual glucose-ketone systems have received CE Mark but are not yet cleared or available for sale in the United States. — The lack of FDA clearance means there is no immediate revenue stream from the US market, creating a regulatory hurdle and delay in commercialization.

-0.20

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

What matters in this story

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

What matters in this story

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Lilly's Van Naarden: Nothing is off the table for dealmaking

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

What matters in this story

Next reads from the same story arc

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott

What matters in this story

Next reads from the same story arc

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

MiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 Outlook

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Lilly's Van Naarden: Nothing is off the table for dealmaking